Mr. Frank Nyhan:

We have had an input into the legislation and been before the committee to discuss it. A lot of what we asked for in terms of regulation has been included in the Bill. The provisions will strengthen our hand and that of the various committees that will ultimately adjudicate in enforcing the regulations. The Vice Chairman is absolutely correct when he says we have an unfortunate reputation, but really that is the perception, rather than being the actual problem. The rate of adverse analytical findings is 0.45% out of approximately 5,000 tests. In the last three years the rate has been 0.8%, just over 0.5% and 0.45%. It is miniscule. However, I accept fully what the Vice Chairman says.

A question was asked about our procedures. They were tested recently in an application before the High Court and, fortunately, held to be correct. We hope that will continue to be the case.

We have invested a lot of money in regulation. In 2017 I think we spent €2 million on various aspects. We will have to continue to do so. If we do not crack the problem, we will not be able to do all of the other things we need to do.